Q-omics provides the consensus-scored PNRC2P1 profile across patient tissues and cancer cell-line models. PNRC2P1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PNRC2P1 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, PNRC2P1 RNA expression shows 14,549 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KICH, and THYM as cancer lineages where PNRC2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNRC2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNRC2P1 survival associations across molecular data types. PNRC2P1 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNRC2P1 RNA expression–survival associations across cancer types. High PNRC2P1 expression shows unfavorable associations in ACC, PAAD and UCEC, but favorable associations in KIRC, SKCM and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for PNRC2P1 RNA expression.
This table summarizes PNRC2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PNRC2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNRC2P1 shows lower tumor expression in KICH, UCEC, COAD, THCA, LUSC and KIRC. The KICH box plot shows higher PNRC2P1 RNA expression in normal versus tumor tissue (log2 FC = −1.181, t-test p = .014).
This table shows molecular features associated with PNRC2P1 in patient tissues and cancer cell lines. In patient samples, PNRC2P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
